FDA Cites Janssen for Misleading Inlexzo Claims

Share

FDA has cited Janssen Biotech over promotional claims suggesting its bladder cancer treatment Inlexzo (gemcitabine intravesical system) can help patients avoid radical cystectomy and prevent progression to muscle-invasive disease, although the clinical trial supporting the drug's approval was not designed to establish either benefit.

In a just-posted untitled letter, CDER Office of Prescription Drug Promotion (OPDP) said the company's healthcare professional website misleadingly characterized findings from the single-arm SunRISe-1 trial, which supported Inlexzo's approval based on complete response and duration of response in patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors.

The website claimed that 84% (57/68) of patients who achieved a complete response did not undergo radical cystectomy, suggesting the drug could preserve patients' bladders. However, FDA said the trial lacked a comparator arm and could not determine whether avoidance of surgery was attributable to Inlexzo or other factors. The agency also rejected the website's disclaimer describing the findings as exploratory, saying it did not adequately correct the misleading impression.

FDA separately challenged claims that 92% (76/83) of evaluable patients did not progress to muscle-invasive bladder cancer. According to OPDP, those data were included in the drug's prescribing information to support a warning about the risk of metastatic bladder cancer associated with delayed cystectomy, not to demonstrate treatment efficacy.

The agency emphasized that radical cystectomy remains the preferred treatment for patients with BCG-unresponsive disease involving carcinoma in situ and that delaying surgery can increase the risk of progression.

OPDP said the promotional claims misbrand Inlexzo under the Federal Food, Drug, and Cosmetic Act. It notes that the agency’s Bad Ad Program also received complaints about promotional communications containing similar representations.

Read more